Novo Nordisk sues Teva over generic drug development

Novo Nordisk has landed in legal dispute with Israeli pharmaceutical company Teva, as the latter company is intending to launch a generic version of Novo Nordisk’s obesity treatment Saxenda.

Photo: Novo Nordisk / PR

According to a filing on the US court database, Novo Nordisk is bringing legal action against Israeli pharmaceutical company Teva, as reported by Danish business daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs